▟ Vinebot intrinsic value, daily

← back

HCA HCA Healthcare

healthcare · valued with opus medium conviction · deep-dived 2026-10-28

STRONG BUY
Intrinsic value$462.05
Price (at call)$449.96
Margin of safety +2.7%
vs market (rating basis) +58.1%

After the rally, HCA's scale franchise trades near fair value, so the margin of safety is gone.

The story

HCA is the largest US for-profit hospital operator, with dense local market clusters that give it pricing power with payers, procurement scale, and operating leverage that smaller systems can't match. It is a mature, cash-generative compounder that grows through volume, acuity, and steady bolt-on capacity, and it returns capital through aggressive buybacks. The main threats are policy: Medicaid cuts, the expiry of exchange subsidies, and site-neutral payment reform. Recent results show resilient volumes and margins holding near 16%.

Drivers are essentially unchanged. Y1 growth nudges up from 5.5% to 6% (not a material move) because TTM revenue of 78.0B is running ahead of the 75.6B fiscal year. Target margin stays at 15.5%, just under the 15.6% TTM, to allow for payer-mix and policy drag. Sales-to-capital of 1.85 and beta of 1.05 still fit a capital-heavy, leveraged operator carrying about 45B of net debt.

Value drivers

Revenue growth (Y1)6.0%
Terminal growth2.5%
Forecast horizon8y
Target operating margin15.5%
Years to target margin7
Sales-to-capital1.85
Beta1.05
Failure probability3.0%
Cost of capital (WACC)8.6%
Terminal WACC8.5%

Valuation bridge

PV of explicit FCFF53.76B
PV of terminal value98.08B
Equity value100.03B
÷ shares → per share$462.05

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 82.69B 6.0% 15.6% 10.21B 2.53B 7.68B 7.07B
2 87.24B 5.5% 15.6% 10.76B 2.46B 8.30B 7.04B
3 91.60B 5.0% 15.6% 11.29B 2.36B 8.93B 6.97B
4 95.73B 4.5% 15.6% 11.78B 2.23B 9.56B 6.87B
5 99.56B 4.0% 15.5% 12.24B 2.07B 10.17B 6.73B
6 103.04B 3.5% 15.5% 12.66B 1.88B 10.77B 6.56B
7 106.13B 3.0% 15.5% 13.02B 1.67B 11.35B 6.37B
8 108.78B 2.5% 15.5% 13.35B 1.43B 11.91B 6.15B

Key risks

  • Medicaid funding cuts and loss of enhanced ACA subsidies raise the uninsured mix and bad debt
  • Site-neutral payment reform and commercial payer pushback compress pricing
  • Labor cost inflation and nurse staffing shortages squeeze margins, and roughly 45B of net debt amplifies equity downside

Catalysts

  • Continued buybacks shrinking the share count at a mid-single-digit annual pace
  • Policy clarity on exchange subsidies and Medicaid supplemental payments that removes the regulatory overhang

History

DatePriceIntrinsicMoSRating
2026-10-28$449.96 $462.05 +2.7% STRONG BUY
2026-09-08$405.00 $484.04 +19.5% STRONG BUY
2026-07-17$385.74 $509.91 +32.2% STRONG BUY
2026-06-23$386.92 $535.22 +38.3% STRONG BUY